The goal is to reach a maintenance dose that provides optimal benefits without causing significant side effects
If you experience symptoms that concern you after starting a compounded GLP-1 medication - severe nausea, vomiting, abdominal pain, or other unexpected reactions - contact your assigned clinical provider through Omzo's care platform first
For those looking to attack stubborn fat, this one shines
Visit FDA MedWatch at www.fda.gov/medwatch or call 1800FDA1088 .
For example, in a prospective study aimed at investigating the influence of GLP-1RA and DPP4 inhibitors on the development of depression in patients with newly diagnosed T2DM, participants receiving incretin-based therapies displayed marked reduction of depressive symptoms after one year, when compared to the control group
The most realistic approval window is late 2027 to 2028